Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNUG01 in ALS
NCT07169175Phase 2Not yet recruiting
- Sponsor
- SineuGene Therapeutics
- Start
- Dec 2025
- Primary completion
- Mar 2028
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 2
01
Overview
A Phase 2 trial of SNUG01 in amyotrophic lateral sclerosis (ALS), sponsored by SineuGene Therapeutics. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
SNUG01
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT07169175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07169175.